| Literature DB >> 30972001 |
Benedikt M Frey1, Marvin Petersen1, Carola Mayer1, Maximilian Schulz1, Bastian Cheng1, Götz Thomalla1.
Abstract
Background: White matter hyperintensities of presumed vascular origin (WMH) are a common finding in elderly people and a growing social malady in the aging western societies. As a manifestation of cerebral small vessel disease, WMH are considered to be a vascular contributor to various sequelae such as cognitive decline, dementia, depression, stroke as well as gait and balance problems. While pathophysiology and therapeutical options remain unclear, large-scale studies have improved the understanding of WMH, particularly by quantitative assessment of WMH. In this review, we aimed to provide an overview of the characteristics, research subjects and segmentation techniques of these studies.Entities:
Keywords: cerebral small vessel disease; large-scale studies; segmentation; systematic review; white matter hyperintensities; white matter hyperintensity segmentation; white matter lesions
Year: 2019 PMID: 30972001 PMCID: PMC6443932 DOI: 10.3389/fneur.2019.00238
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Figure 1Example of segmentation of white matter hyperintensities (WMH) using different approaches The figure shows an example from an own unpublished dataset: (1) FLAIR showing typical distribution of WMH, (2) manual segmentation rater 1 (MP), (3) manual segmentation rater 2 (CM), (4) automated segmentation via Lesion growth algorithm (LGA) of LST toolbox version 2.0.15 (22), (5) automated segmentation via Lesion prediction algorithm (LPA) also of LST toolbox, (6) automated segmentation via the Brain Intensity AbNormality Classification Algorithm (BIANCA) implemented in FSL (23).
Figure 2Flowchart of the search and selection process: the Pubmed research yielded 1,196 articles at baseline. No other sources for article identification were used. After application of exclusion criteria, 137 articles remained.
Characteristics of large-scale study-samples incorporated in this review.
| 3C | 15 | 2008–2017 | 1493 | 72 | HS | Bayesian classifier, supervised, intensity thresholding, semi-automated | Visual rating scales, none | ( |
| ADNI | 3 | 2010–2015 | 752 | 75 | MS: MCI/AD | Markov random field, semi-automated | Semi-automated segmentation | ( |
| AGES-Reykjavik | 7 | 2009–2015 | 3975 | 76 | HS | Artificial neural network, supervised | Manual segmentation | ( |
| ARIC MRI | 4 | 2013–2016 | 1193 | 65 | HS | Intensity thresholding, unsupervised | Manual segmentation | ( |
| ARIC-NCS | 1 | 2017 | 1713 | 75 | MS: Atherosclerosis Risk | Intensity thresholding, unsupervised | Manual segmentation | ( |
| ASPS | 1 | 2016 | 762 | 65 | HS | Intensity thresholding, semi-automated | None | None |
| ASPS/ASPFS | 1 | 2014 | 584 | 67 | HS | Region growing, semi-automated | None | None |
| CDOT | 1 | 2013 | 713 | 70 | MS: DM II | Watershed transformation, unsupervised | Manual segmentation | ( |
| CHAP | 2 | 2010-2014 | 573 | 80 | MS: dementia | Intensity thresholding, semi-automated | Manual segmentation | ( |
| CHARGE | 1 | 2011 | 9361 | 70 | MS: | Miscellaneous | None | None |
| EVA | 1 | 2011 | 780 | 69 | HS | Bayesian classifier, supervised | Visual rating scales | ( |
| FHS | 1 | 2017 | 1527 | 60 | HS | Intensity thresholding, semi-automated | Manual segmentation | ( |
| FOS | 13 | 2007–2018 | 1398 | 62 | HS | Intensity thresholding, semi-automated | Manual segmentation | ( |
| FOS/FHS | 1 | 2005 | 2081 | 62 | HS | Intensity thresholding, semi-automated | Manual segmentation | ( |
| GEN III | 1 | 2016 | 1995 | 46 | HS | Intensity thresholding, semi-automated | Manual segmentation | ( |
| GeneSTAR | 2 | 2014–2015 | 654 | 51 | MS: Relatives of early onset CHD patients | Manual segmentation | None | None |
| GENOA/GMBI | 4 | 2007–2017 | 1182 | 62 | MS: Siblings of hypertensive patients, antihypertensive medication | Intensity thresholding, unsupervised | Manual segmentation | ( |
| HUNT MRI | 1 | 2018 | 862 | 59 | HS | Manual segmentation and freesurfer | None | None |
| ILAS | 1 | 2018 | 802 | 59 | HS | Region growing, unsupervised | None | ( |
| LADIS | 5 | 2007–2016 | 594 | 74 | PS: WMH | Region growing, semi-automated | None | ( |
| LBC 1936 | 6 | 2014–2018 | 676 | 73 | HS | Multispectral coloring modulation and variance identification, unsupervised | Semi-automated segmentation | ( |
| MCSA | 1 | 2016 | 1044 | 78 | HS | Region growing, semi-automated | None | ( |
| NACC UDS (Databank) | 1 | 2018 | 694 | 73 | MS: AD, MCI | Intensity thresholding, semi-automated | Manual segmentation | ( |
| No specific cohort study | 3 | 2010–2016 | 1703 | 65 | MS, PS: Stroke | Intensity thresholding, semi-automated | None | ( |
| NOMAS | 7 | 2011–2018 | 1216 | 70 | HS | Intensity thresholding, semi-automated | Manual segmentation | ( |
| PoP/Sunnybrook | 1 | 2018 | 820 | 71 | MS: AD, MCI, Dementia | Adaptive local thresholding | None | ( |
| PROSPER | 2 | 2006 | 541 | 75 | PS: Vascular disease or high cardiovascular risk | Fuzzy inference system, unsupervised | None | ( |
| RS | 10 | 2007–2018 | 2378 | 62 | HS | k-Nearest neighbor, supervised | Manual segmentation | ( |
| SHIP | 1 | 2016 | 2367 | 52 | HS | Support vector machine, supervised | Manual segmentation | ( |
| SHIP/BLSA | 1 | 2018 | 2143 | 74 | HS | Not specified | None | None |
| SMART-MR | 22 | 2008–2015 | 818 | 58 | PS: Symptomatic atherosclerotic disease | k-Nearest neighbor, supervised | Manual segmentation | ( |
| SNAC-K | 1 | 2016 | 501 | 71 | HS | Manual segmentation | None | None |
| TASCOG/Sydney-MAS | 1 | 2014 | 655 | 75 | HS | Intensity thresholding, unsupervised | Visual rating scales | ( |
| UK Biobank | 2 | 2018 | 8439 | 62 | HS, PS: WMH | k-Nearest neighbor, supervised | Manual segmentation | ( |
| WHICAP | 10 | 2008–2018 | 831 | 77 | HS | Intensity thresholding, semi-automated, fuzzy inference system, unsupervised, region growing, unsupervised | Manual segmentation, Semi-automated segmentation | ( |
| WHICAP/ESPRIT | 1 | 2014 | 1233 | 81 | HS | Region growing, unsupervised | Semi-automated segmentation | ( |
| WHIMS-MRI | 1 | 2014 | 729 | 83 | HS | Support vector machine, supervised | Manual segmentation | ( |
3C, Three-City Study; ADNI, Alzheimer's Disease Neuroimaging Initiative, AGES-Reykjavik, Age, Gene/Environment Susceptibility-Reykjavik Study; ARIC, Atherosclerosis Risk in Communities; ARIC-NCS, Atherosclerosis Risk in Communities Neurocognitive Study; ASPS, Austrian Stroke Prevention Study; ASPFS, Austrian Stroke Prevention Family Study; BLSA, Baltimore Longitudinal Study of Aging; CDOT, Cognition and Diabetes in Older Tasmanians; CHAP, Chicago Health and Aging Project; CHARGE, Multiple studies in CHARGE Consortium; ESPRIT, European/Australasian Stroke Prevention in Reversible Ischemia Trial; EVA, Epidemiology of Vascular Aging; FOS, Framingham Offspring Study; FHS, Framingham Heart Study; GEN III, Third Generation Cohort; GeneSTAR, Genetic Study of Aspirin Responsiveness; GENOA, Genetic Epidemiology Network of Arteriopathy; GMBI, Genetics of Microangiopathic Brain Injury; HUNT, Nord-Trøndelag Health study; LADIS, Leukoaraiosis and DISability Study; LBC1936, Lothian Birth Cohort 1936; MCSA, Mayo Clinic Study of Aging; NACC UDS, National Alzheimer Coordinating Center databank; NOMAS, Northern Manhattan Study; PoP, proof-of-principle cohort; PROSPER, PROspective Study of Pravastatine in the Elderly at Risk of cardiovascular disease; RS, Rotterdam Study; SHIP, Study of Health in Pomerania, SMART-MR, Second Manifestations of Arterial Disease-Magnetic Resonance; SNAC-K, Swedish National study on Aging and Care in Kungsholmen; Sunnybrook, Sunnybrook Dementia study; Sydney-MAS, Sydney Memory and aging study; TASCOG, Tasmanian Study of Cognition and Gait; Sydney MAS, Sydney Memory and Aging Study; WHICAP, Washington Heights-Hamilton Heights-Inwood Community Aging Project; WHIMS, Women's Health Initiative Memory Study; mean age in years; SP, Standard Population; MS, Mixed Sample; PS, Patient Sample; CHD, Coronary heart Disease.
Figure 3Segmentation types and mean sample size of studies on WMH between 2005 and 2018. (A) The blue graph represents the median sample size of the according studies. (B) The blue bars represent the number of large-scale studies for each year included in our review with the specific segmentation type.
Overview of supposed risk factors for WMH in large-scale studies.
| Ad-genetics | |
| Adiposity | |
| Angiotension converting enzyme | |
| Antihypertensive treatment | |
| Aortic stiffness | |
| ApoE genotype | ( |
| Arterial stiffness | ( |
| Atherosclerosis | ( |
| Atrial fibrillation | ( |
| Blood pressure variability | |
| Cardiac stress markers | |
| Cardiovascular risk factors | ( |
| Common risk factors | ( |
| Conjougated equine estrogen | ( |
| Diabetes mellitus type II | ( |
| Diet quality | ( |
| Dysglycemia | |
| Exhaled carbon monoxide | |
| Extracellular vesicle protein levels | |
| FGF23 elevation | |
| Folate | ( |
| Genetic loci | |
| Hba1C | |
| Homocystein | ( |
| Hyperlipidemia | ( |
| Hypertension | ( |
| Inflammatory markers | ( |
| Leisure activity | |
| Lipoproteins | |
| Metabolic syndrome | ( |
| Metalloproteinases | |
| Midlife obesity | ( |
| Nocturnal blood pressure | ( |
| Parathyroid hormon | |
| Parental longevity | |
| Parental stroke | |
| Perceived stress | ( |
| Physical activity | ( |
| Plasma beta-amyloid | |
| Red blood cell omega-3 fatty acid | |
| S100B | ( |
| Sleep duration | |
| Sulfur amino acids | ( |
| Thyroid function | ( |
| Tomm40 523 genotype | ( |
| Uric acid | ( |
| VCAN snps | ( |
| Vitamin B12 | ( |
| Vitamin D | ( |
| Vo2Max | ( |
Common risk factors are age, sex, gender, and ethnicity. Significant associations with WMH indicated in bold.
Overview of supposed sequelae of WMH in large-scale studies.
| Alzheimer's disease | |
| Antidepressant Use | |
| Apathy symptoms | |
| Brain atrophy | ( |
| Brain volumetric changes | ( |
| Callosum atrophy | |
| Cerebral blood flow | |
| Cognitive function | |
| Death | |
| Depressive symptoms | ( |
| Falls | |
| Functional status | |
| Grief | ( |
| Headache | |
| Immobility | |
| Manual dexterity | |
| Migraine | |
| Mild cognitive impairment | ( |
| Olfactory function | ( |
| Perivascular spaces | ( |
| Restless-Legs-syndrome | ( |
| Retinal Microvasculature | |
| Study-drop-out | |
| Subjective memory Impairment | |
| Tract Integrity |
Significant associations with WMH indicated in bold.